Preview

Rational Pharmacotherapy in Cardiology

Advanced search

RIVAROXABAN IN PATIENTS STABILIZED AFTER A ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE ATLAS ACS-2–TIMI-51 TRIAL

https://doi.org/10.20996/1819-6446-2014-10-2-245-252

Full Text:

About the Authors

J. L. Mega

United States


E. Braunwald

United States


S. A. Murphy

United States


A. N. Plotnikov

United States


P. Burton

United States


R. G. Kiss

Hungary


A. Parkhomenko

Ukraine


M. Tendera

Poland


P. Widimsky

Czech Republic


C. M. Gibson

United States


References

1. Roger V.L., Go A.S., Lloyd-Jones D.M., etal. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220.

2. Nabel E.G., Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012;366:54-63.

3. Fox K.A., Anderson F.A.Jr., Goodman S.G., et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med 2008;5: 580-9.

4. Gibson C.M., Mega J.L., Burton P., et al. Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety ofrivaroxaban in subjects with acute coronary syndrome. Am Heart J 2011;161:815-21 e6

5. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.

6. Montalescot G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial. Lancet 2009;373:723-31.

7. Steg P.G., James S., Harrington R.A., et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122: 2131-41.

8. Lemesle G., Paparoni F., Delhaye C., Bonello L., Lablanche J.M. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature. Hosp Pract (Minneap) 2011;39: 32-40.


For citation:


Mega J.L., Braunwald E., Murphy S.A., Plotnikov A.N., Burton P., Kiss R.G., Parkhomenko A., Tendera M., Widimsky P., Gibson C.M. RIVAROXABAN IN PATIENTS STABILIZED AFTER A ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE ATLAS ACS-2–TIMI-51 TRIAL. Rational Pharmacotherapy in Cardiology. 2014;10(2):245-252. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-2-245-252

Views: 471


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)